We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.17B
AUM Growth
+$164M
Cap. Flow
+$76.2M
Cap. Flow %
6.49%
Top 10 Hldgs %
32.39%
Holding
149
New
25
Increased
54
Reduced
51
Closed
11

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
2
CI icon
Cigna
CI
+$11.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$11.1M
4
VTRS icon
Viatris
VTRS
+$10.5M
5
CELG
Celgene Corp
CELG
+$8.17M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12M
2
UNH icon
UnitedHealth
UNH
+$11M
3
ALGN icon
Align Technology
ALGN
+$9.05M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.45M
5
IART icon
Integra LifeSciences
IART
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Industrials 0.76%
3 Technology 0.15%
4 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
51
Vertex Pharmaceuticals
VRTX
$123B
$7.19M 0.61%
42,294
-54,516
-56% -$8.45M
TMO icon
52
Thermo Fisher Scientific
TMO
$198B
$6.03M 0.51%
29,131
+5,283
+22% +$1.12M
REGN icon
53
Regeneron Pharmaceuticals
REGN
$70.9B
$5.96M 0.51%
17,260
-10,120
-37% -$3.17M
WCG
54
DELISTED
Wellcare Health Plans, Inc.
WCG
$5.43M 0.46%
+22,050
New +$4.8M
MOH icon
55
Molina Healthcare
MOH
$11.7B
$5.12M 0.44%
52,240
+8,740
+20% +$762K
BMRN icon
56
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.67M 0.4%
49,519
+5,169
+12% +$453K
COO icon
57
Cooper Companies
COO
$14B
$4.54M 0.39%
77,200
-12,000
-13% -$685K
TRHC
58
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$4.3M 0.37%
67,306
+9,306
+16% +$456K
NBIX icon
59
Neurocrine Biosciences
NBIX
$17.2B
$4.28M 0.36%
43,550
-10,100
-19% -$904K
TFX icon
60
Teleflex
TFX
$5.96B
$3.75M 0.32%
14,000
– –
IART icon
61
Integra LifeSciences
IART
$1.5B
$3.75M 0.32%
58,161
-132,839
-70% -$8.23M
GMED icon
62
Globus Medical
GMED
$10.5B
$3.74M 0.32%
74,045
+25,195
+52% +$1.31M
HSIC icon
63
Henry Schein
HSIC
$10B
$3.73M 0.32%
65,494
+10,669
+19% +$601K
IRTC icon
64
iRhythm Holdings
IRTC
$3.64B
$3.73M 0.32%
45,921
+12,521
+37% +$875K
INCY icon
65
Incyte
INCY
$23.4B
$3.67M 0.31%
54,850
-175,776
-76% -$12M
CERN
66
DELISTED
Cerner Corp
CERN
$3.46M 0.3%
57,900
-6,100
-10% -$361K
ESRX
67
DELISTED
Express Scripts Holding Company
ESRX
$3.44M 0.29%
44,500
-5,000
-10% -$375K
OMCL icon
68
Omnicell
OMCL
$2.09B
$3.35M 0.29%
63,945
+43,945
+220% +$2.07M
XENT
69
DELISTED
Intersect ENT, Inc
XENT
$3.3M 0.28%
88,028
+49,598
+129% +$1.95M
XRAY icon
70
Dentsply Sirona
XRAY
$2.81B
$3.29M 0.28%
75,093
+20,593
+38% +$967K
SGEN
71
DELISTED
Seagen Inc. Common Stock
SGEN
$3.29M 0.28%
49,500
+650
+1% +$37.2K
HZNP
72
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.17M 0.27%
+191,578
New +$2.92M
HMSY
73
DELISTED
HMS Holdings Corp.
HMSY
$3.16M 0.27%
146,069
+92,569
+173% +$1.87M
BHC icon
74
Bausch Health
BHC
$1.8B
$3.02M 0.26%
130,000
+30,000
+30% +$620K
RARE icon
75
Ultragenyx Pharmaceutical
RARE
$2.88B
$3.01M 0.26%
39,150
-1,150
-3% -$74.3K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2018 Portfolio in Review

As of Q2 2018, Bellevue Group held 149 positions worth $1.17B, up 16% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group deployed $76.2M of net new capital in Q2 2018, opening 25 new positions and adding to 54 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Incyte, an estimated $12M trimmed.

  • Bellevue Group's largest Q2 2018 buy was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q2 2018, an estimated $11.9M increase.
  • Bellevue Group's biggest Q2 2018 reduction was Incyte, cutting an estimated $12M.
  • Bellevue Group fully exited Perrigo in Q2 2018, selling an estimated $2.75M.
  • Bellevue Group's ten largest holdings make up 32% of its $1.17B portfolio in Q2 2018.
  • Bellevue Group opened 25 new positions and closed 11 in Q2 2018.
  • Bellevue Group's portfolio value rose 16% quarter-over-quarter to $1.17B.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.